$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000168316824005846 Filed on August 16, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$8.435M	$9.303M
YoY Change	41.59%	67.3%
Cost Of Revenue	$5.569M	$6.947M
YoY Change	40.37%	92.53%
Gross Profit	$2.866M	$2.356M
YoY Change	44.01%	20.66%
Gross Profit Margin	33.98%	25.33%
Selling, General & Admin	$4.255M	$3.881M
YoY Change	41.29%	26.18%
% of Gross Profit	148.47%	164.7%
Research & Development	$126.4K	$436.2K
YoY Change	-46.91%	18.36%
% of Gross Profit	4.41%	18.51%
Depreciation & Amortization	$64.63K	$50.87K
YoY Change	73.68%	45.86%
% of Gross Profit	2.25%	2.16%
Operating Expenses	$4.382M	$4.317M
YoY Change	34.83%	25.35%
Operating Profit	-$1.106M	-$1.268M
YoY Change	41.94%	28.16%
Interest Expense	$123.8K	$430.3K
YoY Change	221.26%	1459.21%
% of Operating Profit
Other Income/Expense, Net	$123.8K	$430.3K
YoY Change	-26.74%	145.61%
Pretax Income	-$982.6K	-$838.0K
YoY Change	60.94%	2.89%
Income Tax	$215.2K	-$343.7K
% Of Pretax Income
Net Earnings	-$1.198M	-$494.3K
YoY Change	83.86%	-45.21%
Net Earnings / Revenue	-14.2%	-5.31%
Basic Earnings Per Share	-$0.94	-$9.94
Diluted Earnings Per Share	-$0.95	-$9.94
COMMON SHARES
Basic Shares Outstanding	1.124M shares	18.95M shares
Diluted Shares Outstanding	1.268M shares	49.73K shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.21M	$11.51M
YoY Change	-35.24%	-41.67%
Cash & Equivalents	$12.21M	$11.51M
Short-Term Investments
Other Short-Term Assets	$735.8K	$1.776M
YoY Change	1739.5%	1559.95%
Inventory	$9.821M	$8.491M
Prepaid Expenses	$735.8K	$1.776M
Receivables	$3.219M	$3.974M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$25.98M	$25.75M
YoY Change	2.15%	-1.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$590.8K	$541.4K
YoY Change	76.4%	47.65%
Goodwill
YoY Change
Intangibles	$2.943M	$2.447M
YoY Change	141.96%	98.38%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.075M	$3.552M
YoY Change	83.94%	53.7%
TOTAL ASSETS
Total Short-Term Assets	$25.98M	$25.75M
Total Long-Term Assets	$4.075M	$3.552M
Total Assets	$30.06M	$29.30M
YoY Change	8.7%	3.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.157M	$4.930M
YoY Change	87.19%	180.15%
Accrued Expenses	$116.3K	$114.5K
YoY Change	-3.13%	-6.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.528M	$5.299M
YoY Change	-11.0%	13.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$440.3K	$462.9K
YoY Change	-21.38%	-22.44%
Total Long-Term Liabilities	$489.0K	$511.6K
YoY Change	-18.32%	-20.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.528M	$5.299M
Total Long-Term Liabilities	$489.0K	$511.6K
Total Liabilities	$5.018M	$5.811M
YoY Change	-11.77%	9.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.88M	-$65.68M
YoY Change	6.74%	5.93%
Common Stock	$2.000K	$1.171K
YoY Change	-92.21%	-95.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.04M	$23.49M
YoY Change
Total Liabilities & Shareholders Equity	$30.06M	$29.30M
YoY Change	8.7%	3.14%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$1.198M	-$494.3K
YoY Change	83.86%	-45.21%
Depreciation, Depletion And Amortization	$64.63K	$50.87K
YoY Change	73.68%	45.86%
Cash From Operating Activities	-$1.361M	-$4.578M
YoY Change	195.86%	21.17%
INVESTING ACTIVITIES
Capital Expenditures	$609.5K	$572.2K
YoY Change	5995.2%	94.48%
Acquisitions
YoY Change
Other Investing Activities	$31.15K	$29.98K
YoY Change	3.83%	-13.75%
Cash From Investing Activities	-$578.4K	-$542.2K
YoY Change	-2991.85%	108.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.866M	-28.53K
YoY Change	-3209.92%	-100.7%
NET CHANGE
Cash From Operating Activities	-1.361M	-4.578M
Cash From Investing Activities	-578.4K	-542.2K
Cash From Financing Activities	1.866M	-28.53K
Net Change In Cash	-73.38K	-5.149M
YoY Change	-85.32%	-25276.09%
FREE CASH FLOW
Cash From Operating Activities	-$1.361M	-$4.578M
Capital Expenditures	$609.5K	$572.2K
Free Cash Flow	-$1.970M	-$5.150M
YoY Change	319.25%	26.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1124341	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11507745	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3973550	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	8490745	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1776480	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	25748520	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	541410	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2447128	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	563920	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	3552458	usd
CY2024Q2	us-gaap	Assets Assets	29300978	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4930055	usd
CY2024Q2	SBFM	Earnout Payable EarnoutPayable	0	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	254971	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	114452	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5299478	usd
CY2024Q2	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	48729	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	462906	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	511635	usd
CY2024Q2	us-gaap	Liabilities Liabilities	5811114	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	13000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1170510	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1170510	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14012	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14012	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1171	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89842503	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-683050	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65683759	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	23489865	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29300978	usd
CY2024Q2	us-gaap	Revenues Revenues	9303067	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	6946810	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	2356257	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	88394	usd
CY2024Q2	SBFM	Consulting Expense ConsultingExpense	54048	usd
CY2023Q2	SBFM	Consulting Expense ConsultingExpense	392454	usd
	SBFM	Consulting Expense ConsultingExpense	101449	usd
	SBFM	Consulting Expense ConsultingExpense	524069	usd
CY2024Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2024Q2	us-gaap	Legal Fees LegalFees	223436	usd
CY2024Q2	us-gaap	Marketing Expense MarketingExpense	256325	usd
CY2024Q2	SBFM	Office Expense OfficeExpense	713245	usd
CY2023Q2	SBFM	Office Expense OfficeExpense	419650	usd
	SBFM	Office Expense OfficeExpense	1673636	usd
	SBFM	Office Expense OfficeExpense	938768	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	436235	usd
CY2024Q2	us-gaap	Salaries And Wages SalariesAndWages	1556176	usd
CY2024Q2	SBFM	Taxes Taxes	145805	usd
CY2023Q2	SBFM	Taxes Taxes	96649	usd
	SBFM	Taxes Taxes	221706	usd
	SBFM	Taxes Taxes	160367	usd
CY2024Q2	us-gaap	Depreciation Depreciation	50870	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3624533	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1268276	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	286535	usd
CY2024Q2	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	143995	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	245	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	430285	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-837991	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-343691	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-494300	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-835450	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1329750	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-218.62
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12675	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40896	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11914	shares
	us-gaap	Net Income Loss NetIncomeLoss	-1778101	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2604538	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	93494	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69594	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	12000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1867693	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55160	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2949128	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	885243	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	272810	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-182852	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2794798	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1103502	usd
	SBFM	Increase Decrease In Earnout Payable IncreaseDecreaseInEarnoutPayable	2547831	usd
	SBFM	Increase Decrease In Earnout Payable IncreaseDecreaseInEarnoutPayable	1084169	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1247671	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-147980	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7762942	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5628146	usd
	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	61074	usd
	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	66846	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	234569	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17645	usd
	SBFM	Payments For Proceeds From Acquire Property Plant And Equipment PaymentsForProceedsFromAcquirePropertyPlantAndEquipment	1037450	usd
	SBFM	Payments For Proceeds From Acquire Property Plant And Equipment PaymentsForProceedsFromAcquirePropertyPlantAndEquipment	454980	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1210944	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-405779	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8522411	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	4089208	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	45000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1156	usd
	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	3139651	usd
	SBFM	Purchase Of Treasury Stock PurchaseOfTreasuryStock	506822	usd
	SBFM	Payment For Lease Liability PaymentForLeaseLiability	58194	usd
	SBFM	Payment For Lease Liability PaymentForLeaseLiability	63870	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5369566	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3519672	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16292347	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3604320	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2514253	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1180282	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	417298	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11507745	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19729491	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	956012	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	SBFM	Stock Issued For Services StockIssuedForServices	12000	usd
	SBFM	Stock Issued For Services StockIssuedForServices	0	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	24819615	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1329750	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	23489865	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4089218	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1156	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-410059	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23109793	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21207361	usd
	SBFM	Preferred Stock Issued To Related Party PreferredStockIssuedToRelatedParty	12000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8522411	usd
	SBFM	Repurchase Warrants RepurchaseWarrants	-3139651	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3157256	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	23489865	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
	SBFM	Repurchase Stock RepurchaseStock	-506822	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4089218	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1156	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2101329	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23109793	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-100
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1444259	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	776856	usd
	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	1077380	usd
CY2023	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	710372	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2521639	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1487228	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	74511	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	42969	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2447128	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1444259	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	73257	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	73257	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	73257	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	39300	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1889	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	35714	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1170510	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1170510	shares
	us-gaap	Dividends Dividends	0	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-494300	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-902108	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49726	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12675	shares
CY2024Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2023Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49726	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12675	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.94
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-71.17
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	563920	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	114452	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	462906	usd
	SBFM	Lessee Operating Leases Remaining Lease Term LesseeOperatingLeasesRemainingLeaseTerm	5 years 6 months
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	56479	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	114859	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	108790	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	102470	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	96517	usd
CY2024Q2	SBFM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	98243	usd
CY2024Q2	us-gaap	Officers Compensation OfficersCompensation	1120356	usd
CY2023Q2	us-gaap	Officers Compensation OfficersCompensation	225000	usd
	us-gaap	Officers Compensation OfficersCompensation	1382842	usd
	us-gaap	Officers Compensation OfficersCompensation	1045000	usd
CY2023Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-343691	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-321338	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87677	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	133947	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-005846-index-headers.html	Edgar Link	pending
0001683168-24-005846-index.html	Edgar Link	pending
0001683168-24-005846.txt	Edgar Link	pending
0001683168-24-005846-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20240630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
sbfm-20240630_def.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10q-063024.htm	Edgar Link	pending
sunshine_logo.jpg	Edgar Link	pending
sbfm-20240630_lab.xml	Edgar Link	unprocessable
sbfm-20240630_pre.xml	Edgar Link	unprocessable
sunshine_i10q-063024_htm.xml	Edgar Link	completed
sbfm-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2024 Q3 Form 10-Q Financial Statement

#000168316824005846 Filed on August 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2024 Q3 Form 10-Q Financial Statement

#000168316824005846 Filed on August 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm